monoclonal antibodies

Jul 15, 2026

For most of medical history, treating disease meant casting a wide net. Chemotherapy attacked every fast-dividing cell it could find, healthy or cancerous. Broad-spectrum drugs treated symptoms without ever asking why a particular patient's biology behaved the way it did. That era is ending. Targeted therapeutics, ...

Jul 13, 2026

Summary ILD is a heterogeneous group of 200+ chronic lung disorders marked by inflammation and progressive scarring that cause worsening breathlessness, declining lung function, and shortened life expectancy. Monoclonal antibodies (mAbs) are reshaping ILD care by precisely targeting inflammatory and fibrotic...

Sep 24, 2024

The landscape of multiple myeloma therapies has been revolutionized by the introduction of cutting-edge monoclonal antibodies (mAbs) targeting CD38. Among the standout advancements are DARZALEX (daratumumab) and SARCLISA (isatuximab-irfc), which have emerged as game-changers in the treatment of multiple myeloma. Th...

Jul 30, 2024

Multiple Myeloma, the second most common type of blood cancer after non-Hodgkin lymphoma, is characterized by the presence of malignant plasma cells in the bone marrow. The diagnosis involves identifying these highly abnormal and unstable cells, which proliferate aggressively and spread through the bloodstream and ...

Jan 03, 2022

An antibody is a protein produced by the immune system in response to an infection in the body. Whereas, a monoclonal antibody is a molecule produced in a laboratory specifically designed to enhance the body’s natural immune system response against an invader, such as cancer or an infection. Monoclonal antibodies h...

Jan 10, 2019

Apollomics raises USD 100 Million for funding of transpacific cancer R&D plan Apollomics has raised USD 100 million for funding an oncology clinical trial program. The series B round sets Apollomics to progress its c-Met inhibitor and pipeline of other clinical-phase assets. OrbiMed Asia-backed Apo...

Aug 30, 2018

For all-in-one dialysis system, Outset Medical captures USD 132 Million to extend U.S. expansion Outset Medical bagged USD132 Million in series D capital. This ensued in encouraging the production capabilities and accelerating the commercial expansion for all-in-one dialysis system. The FDA cleared the Tablo Hemodia...